Drugs / Ixmyelocel-T
Ixmyelocel-T
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01616953 | Aug 2012 → Jun 2015 | cleft palate | University of Michigan | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT01670981 | Feb 2013 → Feb 2016 | dilated cardiomyopathy | Vericel Corporation | Completed | Met primary |
| Phase 2 | NCT01020968 | Dec 2009 → Jan 2012 | dilated cardiomyopathy | Vericel Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00765518 | Sep 2008 → Sep 2012 | dilated cardiomyopathy | Vericel Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00468000 | Apr 2007 → Mar 2011 | peripheral arterial disease | Vericel Corporation | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01483898 | Feb 2012 → Mar 2014 | limb ischemia | Vericel Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00505219 | Sep 2007 → Sep 2010 | osteonecrosis | Vericel Corporation | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ixmyelocel-T | “alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)” NCT01616953 ↗ |
| Known as | Cardiac Repair Cell | “Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)” NCT00765518 ↗ |
| Known as | Catheter-based Cardiac Repair Cell | “Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy” NCT01020968 ↗ |
| Known as | CRC | “Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy” NCT01020968 ↗1“Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)” NCT00765518 ↗ |
| Known as | TRC Autologous Bone Marrow Cells | “Use of Ixmyelocel-T (Formerly TRC Autologous Bone Marrow Cells) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia” NCT00468000 ↗ |
| Known as | Vascular Repair Cells [VRC] | “Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia” NCT00468000 ↗ |
| Modality | Cell therapy | “Cellular therapy with Ixmyelocel-T to treat critical limb ischemia” PMID 22453769 ↗ Mar 2012 |
| Route | Intramuscular | “compared the efficacy and safety of intramuscular injections of ixmyelocel-T with placebo” PMID 22453769 ↗ Mar 2012 |